For US residents only
How LUTATHERA May Help
Clinical Trial Results for LUTATHERA
In a clinical trial, 229 people with midgut NETs who received LUTATHERA® (lutetium Lu 177 dotatate) injection for intravenous use in combination with 30 mg of long-acting octreotide were compared with those who received 60 mg of long-acting octreotide alone.
Longer Progression-Free Survival (PFS) for Patients Treated With LUTATHERA
aTumors shrink to ≥30% from baseline.
bTumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.